Navigation Links
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
Date:10/23/2008

ung function.

Results from this clinical trial indicated that MP-376 was well tolerated, with no serious drug related adverse events reported. Dose escalation proceeded successfully through the highest planned dose with no dose limiting toxicities. PK results also met expectations, with sputum drug levels increasing with increasing doses of inhaled MP-376.

Although this trial was not designed as an efficacy study, evidence of drug activity was observed in this trial. Patients receiving MP-376 experienced a reduction in P. aeruginosa counts well in excess of one log on average after 14 days of treatment, whereas counts in placebo treated patients increased slightly over the treatment period. In addition, FEV1, a standard measure of lung function, showed dose-related improvements in MP-376 treated patients, with the highest dose group experiencing increases in FEV1 of greater than 15%.

"The results from this study are very encouraging," stated Dr. Jeff Loutit, Chief Medical Officer of Mpex Pharmaceuticals. "The safety and PK results were consistent with our expectations and support advancing the compound into larger clinical trials. Furthermore, the effects seen on bacterial counts and pulmonary function give us confidence as we move MP-376 through development. This is particularly true given that the results were obtained in a patient population that had significant prior inhaled antibiotic experience and many patients were infected with multi-drug resistant P. aeruginosa."

Based on these results Mpex initiated a 28-day Phase 2 study in 140 CF patients earlier this year at sites in the U.S., Germany and the Netherlands. This study is expected to complete enrollment in the second quarter of 2009. Results from this study, if successful, are expected to allow Mpex to choose the optimal dosing regimen for Phase 3 clinical trials anticipated to begin later in 2009.

Preclinical Results

MP-376 was designed to address many of the sho
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Critical Pharmaceuticals Enter Sustained Release hGH Arena
11. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Calif. , May 23, 2013 Amgen (NASDAQ: ... 38 th Annual  Healthcare Conference on Thursday, May 30, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... at Amgen, will present at the conference. Live audio of ... Amgen,s website, www.amgen.com , under Investors. A replay of ...
(Date:5/23/2013)... HOUSTON , May 23, 2013  A recently ... in Houston, Texas , demonstrates that ... simultaneously increasing cancer detection. The study, ... An Observational Study," was led by Stephen ... June issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... 2013 Anthem Blue Cross patients with HIV/AIDS ... them to obtain their medications by mail order under ... Kallas LLC.  The lawsuit, filed in ... Cross,s mandatory mail order program announced late last year ... "This settlement brings to a close a ...
Breaking Medicine Technology:First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... , CAMBRIDGE, Mass., Dec. 3, 2009 ... (NYSE: RTN ), has licensed its patented, award-winning ... FUJIFILM intends to interface the SDM technology with the Aspire ... digital mammography system will deliver stereo images for 3-D viewing. ...
... , , MAPLE ... the next phase of its strategic plan for central nervous ... developed program for the management of epilepsy. USL255 is being ... phase III clinical trial in early 2010 for the adjunctive ...
Cached Medicine Technology:Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 3Upsher-Smith Announces Milestone in Development of CNS Strategy 2
(Date:5/26/2013)... "While the risk of infection following ... should be aware of the potential complications that can ... said Dr. Sadati. "It helps them to be more ... the blog, Dr. Sadati notes that less ... post-operative infection. However, patients who are undergoing any type ...
(Date:5/26/2013)... 26th May, 2013: While coupons can be ... use them. Be it due to a bad experience in ... only a few people who actually make use of coupons. ... spread awareness about coupons and allow people to use them ... there being various different opinions on why shoppers resist couponing, ...
(Date:5/26/2013)... Pain is an overall condition of sensory discomfort ... as acute pain and chronic. Pain has always been ... help. Every year about half a million people succumb ... used as primary pain relievers in which they decrease ... reducing the transmit of pain. Most common methods of ...
(Date:5/26/2013)... , , FRIDAY, May 24 (HealthDay News) -- We,ve all seen ... hurricane hits, the guy who decides to ride out the ... steer their cars alongside a scary-looking funnel cloud. Monday,s ... that Mother Nature isn,t something to gamble with -- that ... still get hurt and die. Yet, even now, when ...
(Date:5/26/2013)... May 26, 2013 According to a ... Medium Caliber & Small Caliber] (2012 – 2017)”, published ... reach $8.15 Billion by 2017 with a CACR of ... Data Tables , 87 Figures , ... “Ammunition Market” , http://www.marketsandmarkets.com/Market-Reports/ammunition-market-923.html , ...
Breaking Medicine News(10 mins):Health News:Orange County Surgeon Discusses the Risk of Infection after a Cosmetic Surgery 2Health News:Living on a Coupon Launched - Jessica Hacker Aims to Bring Professional Couponing Tips to the Masses 2Health News:Pain Management Drugs And Devices Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Pain Management Drugs And Devices Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Storm Chasers: Born to Be Wild? 2Health News:Storm Chasers: Born to Be Wild? 3Health News:Ammunition Market to Reach $8.15 Billion by 2017 at a CACR of 0.67% - New Report by MarketsandMarkets 2Health News:Ammunition Market to Reach $8.15 Billion by 2017 at a CACR of 0.67% - New Report by MarketsandMarkets 3Health News:Ammunition Market to Reach $8.15 Billion by 2017 at a CACR of 0.67% - New Report by MarketsandMarkets 4
... American Academy of Pediatrics (AAP) recommended all babies should ... deaths from Sudden Infant Death Syndrome have declined dramatically. ... and asphyxia, have increased. In an updated ... its guidelines on safe sleep for babies, with additional ...
... an association between shift work and increased risk of multiple ... age of 20 may be at risk for MS due ... Findings of this novel study appear today in Annals ... of the American Neurological Association and Child Neurology Society. ...
... the University of Sheffield is set to tackle the grand ... The FUTURAGE Road Map, created by Alan Walker, ... of Sociological Studies, will provide the European research agenda for ... was launched today at a meeting of the European Parliament ...
... more than half of cancer-free women will be among those ... about one in 12 will be referred for a biopsy. ... woman,s probability of having one of these false-positive episodes by ... over the course of a decade. A new ...
... October 17, 2011 (BRONX, NY) The Eunice ... Development, part of the National Institutes of Health, has ... Medicine of Yeshiva University $5.7 million to fund ... Disabilities Research Center (IDDRC). The grant supports Einstein,s ...
... , NEW YORK, October 17, 2011 -- Prof. ... (BGU), recently received the U.S. National Distinguished International Scientist ... Alcohol and Drug Abuse Resources (RADAR) Center. This ... National Institute on Drug Abuse (NIDA), which works with ...
Cached Medicine News:Health News:AAP expands guidelines for infant sleep safety and SIDS risk reduction 2Health News:AAP expands guidelines for infant sleep safety and SIDS risk reduction 3Health News:Shift work in teens linked to increased multiple sclerosis risk 2Health News:Project leads next decade of ageing research across Europe 2Health News:Project leads next decade of ageing research across Europe 3Health News:Project leads next decade of ageing research across Europe 4Health News:High rate of false-positives with annual mammogram 2Health News:High rate of false-positives with annual mammogram 3Health News:Einstein College of Medicine receives $5.7 million for developmental disabilities research 2Health News:BGU professor receives US National Distinguished International Science Award for substance abuse work 2
... SP Surgical Table combines innovation and design ... up to 1,000 lbs. You can safely ... normal and reverse orientation and have virtually ... patients.,The Amsco 3085 SP Table offers the ...
... 1st MPJ IMPLANT SYSTEM is a unique ... of the 1st metatarsal phalangeal joint resulting ... revision of a previous arthroplasty. The ... pain relief, superior function and longevity. ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
Medicine Products: